SAN DIEGO

,

May 25, 2021

/PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that its CEO Saundra Pelletier will present at the 2021 LD Micro Invitational XI on

Tuesday, June 8, 2021

at

1:00 p.m. ET

(

10:00 a.m. PT

).

Pelletier will provide an update on the commercialization of Evofem’s hormone-free contraceptive


Phexxi® (lactic acid, citric acid and potassium bitartrate)


, the ongoing Phase 3 clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea in women, and other ongoing initiatives.

To pre-register for the presentation, please visit

https://ldmicrojune2021.mysequire.com/

.

About Evofem Biosciences


Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). For more information, please visit

evofem.com

.

Phexxi

^®

is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact



Amy Raskopf


Evofem Biosciences, Inc.



[email protected]



Mobile: (917) 673-5775

View original content to download multimedia:

http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-ld-micro-invitational-xi-on-tuesday-june-8-2021-301298297.html

SOURCE Evofem Biosciences, Inc.